Boothbay Fund Management’s Celldex Therapeutics CLDX Stock Holding History

Boothbay Fund Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.21M	Buy	140,064 +5,119	+4%	+$165K	0.07%	339
2026 Q1	$4.28M	Buy	+134,945	New	+$3.68M	0.06%	361
2023 Q2	–	Sell	-19,576	Closed	-$704K	–	1881
2023 Q1	$704K	Sell	19,576 -11,697	-37%	-$505K	0.01%	1140
2022 Q4	$1.39M	Sell	31,273 -5,845	-16%	-$209K	0.03%	752
2022 Q3	$1.04M	Sell	37,118 -24,947	-40%	-$765K	0.03%	847
2022 Q2	$1.67M	Hold	62,065	–	–	0.04%	613
2022 Q1	$2.11M	Buy	62,065 +16,615	+37%	+$531K	0.05%	564
2021 Q4	$1.76M	Buy	45,450 +19,041	+72%	+$830K	0.04%	523
2021 Q3	$1.43M	Sell	26,409 -25,929	-50%	-$1.22M	0.04%	591
2021 Q2	$1.75M	Sell	52,338 -21,861	-29%	-$600K	0.06%	435
2021 Q1	$1.53M	Sell	74,199 -105,471	-59%	-$2.42M	0.06%	422
2020 Q4	$3.15M	Sell	179,670 -6,447	-3%	-$116K	0.12%	156
2020 Q3	$2.76M	Sell	186,117 -22,719	-11%	-$266K	0.17%	145
2020 Q2	$2.71M	Buy	+208,836	New	+$926K	0.19%	140

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's CLDX Position: Q2 2026 in Review

Boothbay Fund Management increased its Celldex Therapeutics (CLDX) stake by 3.8% in Q2 2026, buying an estimated $165K and bringing the position to 140,064 shares worth $5.21M. The position accounts for 0.07% of the portfolio, ranked #339.

Boothbay Fund Management first reported a position in CLDX in Q2 2020 and has held it in 14 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Boothbay Fund Management held 140,064 shares of Celldex Therapeutics worth $5.21M as of Q2 2026.
Boothbay Fund Management bought 5,119 Celldex Therapeutics shares in Q2 2026, an estimated $165K.
Celldex Therapeutics made up 0.07% of Boothbay Fund Management's portfolio in Q2 2026, its #339 holding.
Boothbay Fund Management first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 14 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.